文献速递泌尿生殖介入CT

BioXmark®液体基准标记物用于肌层浸润性膀胱癌影像引导放疗的安全性与性能试验

BioXmark® liquid fiducial markers for image-guided radiotherapy in muscle invasive bladder cancer: a safety and performance trial.
PubMed 文献 · Br J Radiol · 2020-06-01

这项前瞻性单中心I-II期研究纳入20例肌层浸润性膀胱癌患者,经柔性膀胱镜在肿瘤周围注射BioXmark®液体标记物,评估计划CT与CBCT上的可见性和稳定性。共植入76枚标记物,CT可见率为79%(95%CI±9%),超过预设75%成功阈值;未见BioXmark®相关不良事件,可见标记物在末次CBCT上均未移位。

要点

  • CT上标记物可见率为79%(95%CI±9%),超过预设75%成功阈值。
  • 末次CBCT上所有CT可见标记物均仍可检出且无移位,位置稳定。
  • 未见BioXmark®相关不良事件,作者认为其似乎安全且易于注射。

核心结论

  • 该新型基准标记物的成功率为79%,高于预设阈值率。
  • 研究期间观察到液体标记物注射存在明显学习曲线。
  • 标记物在治疗阶段表现出持续可见性和位置稳定性,且似乎安全、易于注射。

研究设计与样本

  • 前瞻性单中心I-II期研究,共纳入20例肌层浸润性膀胱癌患者。
  • 经柔性膀胱镜在肿瘤周围注射BioXmark®液体标记物。
  • 在计划CT和CBCT上评估标记物可见性与稳定性,预设成功阈值为可见率75%。

关键影像表现/征象

  • 20例患者共植入76枚标记物,其中60枚(79%,95%CI±9%)在CT扫描上可见。
  • 由于技术学习曲线,后75%患者的可见率为86%,前25%患者的可见率为58%。
  • CT采集后所有可见标记物在末次CBCT上仍可检出且无移位。
  • 15/20例(75%)患者在CT上可见三个或以上标记物。
  • 未报告BioXmark®相关不良事件。

诊断标准与关键数值

  • 预设成功阈值:标记物可见率75%。
  • CT可见率79%(95%CI±9%),高于预设75%阈值。

临床应用与阅片要点

  • 作者认为该新型液体BioXmark®标记物似乎是日常自适应IGRT中用于肌层浸润性膀胱癌保留膀胱放化疗的很有前景的工具。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: This study evaluated the performance of the novel liquid fiducial marker (BioXmark®) in IGRT for bladder cancer.

METHODS: 20 patients with muscle invasive bladder cancer were entered in this prospective, single center, Phase I-II study. The novel BioXmark® liquid markers were injected around the tumor using a flexible cystoscopy. Visibility and stability of the markers were evaluated on planning-CT and CBCT. Prospectively defined threshold for success was set at a visibility of 75%.

RESULTS: In total, 76 markers were implanted in 20 patients. Of those, 60 (79% 95% CI ± 9%) were visible on CT scan. Due to the learning curve of the technique, the visibility improved in the last 75% of patients (86% visibility) compared to the first 25% of patients with 58% visibility. Concerning stability of the BioXmark® marker, all visible markers after CT acquisition were still detectable at the last CBCT without displacement. In 15/20 (75%) of the patients, three or more markers were visible on CT. No BioXmark® related adverse events were reported.

CONCLUSION: The success rate of this novel fiducial marker was 79%, which is above the prospectively defined threshold rate. A distinct learning curve of the injection of the liquid marker was seen over the study period. The marker showed sustained visibility and positional stability during treatment phases and also appears to be safe and easy to inject.

ADVANCES IN KNOWLEDGE: This novel liquid BioXmark® marker seems to be a very promising tool in daily-adaptive IGRT for bladder preserving chemoradiotherapy in muscle invasive bladder cancer.

来源:Br J Radiol,查看原文。版权归原作者所有。

引用

  1. de Ridder M, Gerbrandy LC, de Reijke TM, et al. BioXmark® liquid fiducial markers for image-guided radiotherapy in muscle invasive bladder cancer: a safety and performance trial. Br J Radiol. 2020. PMID: 32463291. doi:10.1259/bjr.20200241

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。